Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

NASDAQ:XXII - Nasdaq - US90137F4000 - Common Stock - Currency: USD

8.43  -0.29 (-3.33%)

Fundamental Rating

3

Taking everything into account, XXII scores 3 out of 10 in our fundamental rating. XXII was compared to 8 industry peers in the Tobacco industry. The financial health of XXII is average, but there are quite some concerns on its profitability. XXII has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XXII had negative earnings in the past year.
XXII had a negative operating cash flow in the past year.
XXII had negative earnings in each of the past 5 years.
XXII had a negative operating cash flow in each of the past 5 years.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -95.38%, XXII is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
The Return On Equity of XXII (-564.61%) is worse than 62.50% of its industry peers.
Industry RankSector Rank
ROA -95.38%
ROE -564.61%
ROIC N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

XXII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XXII has been increased compared to 1 year ago.
XXII has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XXII has an improved debt to assets ratio.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

XXII has an Altman-Z score of -25.15. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.
XXII has a worse Altman-Z score (-25.15) than 75.00% of its industry peers.
XXII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.15
ROIC/WACCN/A
WACC9.91%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.68 indicates that XXII may have some problems paying its short term obligations.
The Current ratio of XXII (0.68) is worse than 75.00% of its industry peers.
XXII has a Quick Ratio of 0.68. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of XXII (0.52) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.52
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.13% over the past year.
XXII shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.76%.
The Revenue has been decreasing by -1.15% on average over the past years.
EPS 1Y (TTM)99.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.37%
Revenue 1Y (TTM)-19.76%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%93.13%

3.2 Future

XXII is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.03% yearly.
The Revenue is expected to grow by 24.06% on average over the next years. This is a very strong growth
EPS Next Y89.2%
EPS Next 2Y44.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.73%
Revenue Next 2Y24.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 0 -5K -10K -15K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
XXII is valuated cheaply with a Price/Forward Earnings ratio of 5.58.
100.00% of the companies in the same industry are more expensive than XXII, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.03. XXII is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 5.58
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

XXII's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XXII's earnings are expected to grow with 44.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.03%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XXII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (6/23/2025, 10:47:19 AM)

8.43

-0.29 (-3.33%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners3.97%
Inst Owner Change2.53%
Ins Owners26.38%
Ins Owner Change0.49%
Market Cap53.70M
Analysts82.86
Price TargetN/A
Short Float %5.31%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-15.75%
Min Revenue beat(2)-55.74%
Max Revenue beat(2)24.24%
Revenue beat(4)1
Avg Revenue beat(4)-17.1%
Min Revenue beat(4)-55.74%
Max Revenue beat(4)24.24%
Revenue beat(8)1
Avg Revenue beat(8)-22.16%
Revenue beat(12)3
Avg Revenue beat(12)-21.35%
Revenue beat(16)4
Avg Revenue beat(16)-17.18%
PT rev (1m)0%
PT rev (3m)-7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)85.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2.67%
Revenue NY rev (3m)-15.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.58
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 14.81
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-122.83
EYN/A
EPS(NY)1.51
Fwd EY17.91%
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.37
OCFYN/A
SpS3.75
BVpS0.57
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.38%
ROE -564.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-239.28%
ROA(5y)-159.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.16%
Cap/Sales 0.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.52
Altman-Z -25.15
F-Score5
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)104.4%
Cap/Depr(5y)87.56%
Cap/Sales(3y)9.68%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.37%
EPS Next Y89.2%
EPS Next 2Y44.03%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.76%
Revenue growth 3Y-7.64%
Revenue growth 5Y-1.15%
Sales Q2Q%93.13%
Revenue Next Year-12.73%
Revenue Next 2Y24.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.74%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.42%
OCF growth 3YN/A
OCF growth 5YN/A